Condition / Treatment skin-conditions

Psoriasis and Phototherapy

Psoriasis is a chronic, immune‑mediated skin disease marked by well‑demarcated, scaly plaques that can itch, crack, and bleed. Variants include chronic plaque (most common), guttate, inverse, pustular, and erythrodermic psoriasis. Beyond the skin, many people experience nail changes and joint inflammation (psoriatic arthritis). The condition carries a significant burden: visible lesions affect quality of life, and systemic inflammation links to cardiometabolic risk. Light‑based therapies target core disease biology by slowing overactive keratinocyte proliferation and dialing down T‑cell–driven inflammation in the skin. Phototherapy encompasses several modalities. Narrowband UVB (NB‑UVB, 311–313 nm) is the modern standard for widespread plaque psoriasis. It is typically delivered 2–3 times weekly over 8–12 weeks, with incremental dose increases based on skin response. Broadband UVB (BB‑UVB, 290–320 nm) is less selective and more erythemogenic, now used less often. PUVA combines UVA (320–400 nm) with a photosensitizer (psoralen) administered orally or via bath; it penetrates deeper and can be more effective for very thick or extensive plaques, usually given 2–3 times weekly for 6–10 weeks. Home NB‑UVB units, prescribed and supervised by specialists, offer a convenient alternative for selected patients. Biologically, UV light induces T‑cell apoptosis, reduces pro‑inflammatory cytokines (e.g., IL‑17/IL‑23 axis activity), and normalizes keratinocyte growth and differentiation. Evidence supports phototherapy’s efficacy. Many patients achieve marked improvement or clearance: NB‑UVB often yields 60–75% clearance rates after 20–30 sessions, with visible improvement by weeks 3–6; PUVA can reach 70–90% clearance in fewer sessions and may produce longer remissions. Relapse is common months after stopping; some use short maintenance courses. Compared with topical therapy, phototherapy offers broader control for moderate disease; versus systemic agents, NB‑UVB can be comparable

Updated March 22, 2026

This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any supplement or medication regimen.

Overlapping Treatments

Topical corticosteroids (with phototherapy)

Moderate Evidence
Benefits for Psoriasis

Enhances plaque reduction and itch relief; useful on thick or inflamed lesions

Benefits for Phototherapy

Reduces erythema, allows lower UV dose and faster response

Potential skin atrophy with prolonged use on thin skin; coordinate application timing to avoid blocking UV if using occlusion

Vitamin D analogs (calcipotriol/calcipotriene)

Moderate Evidence
Benefits for Psoriasis

Improves scaling and plaque thickness; synergistic with UVB

Benefits for Phototherapy

Dose‑sparing effect; may speed clearance when alternated with UVB

Can irritate sensitive areas; avoid immediate pre‑exposure application that may affect light penetration

Emollients (bland moisturizers)

Strong Evidence
Benefits for Psoriasis

Reduces scaling, fissuring, and itch; improves barrier

Benefits for Phototherapy

Improves UV penetration by reducing surface scale; enhances tolerability

Apply consistently; avoid products with photosensitizers unless prescribed

Acitretin plus UV (Re‑UVB/Re‑PUVA)

Moderate Evidence
Benefits for Psoriasis

Greater clearance and longer remission in severe/thick plaques

Benefits for Phototherapy

Reduces cumulative UV dose needed for response

Teratogenic; strict pregnancy avoidance; mucocutaneous side effects; liver/lipid monitoring required

Biologic agents (e.g., TNF‑α, IL‑17, IL‑23 inhibitors) with phototherapy

Emerging Research
Benefits for Psoriasis

Rapid and deeper lesion control in refractory cases

Benefits for Phototherapy

Shortens time to response, may allow fewer UV sessions

Adds immunosuppression; balance potential UV risks; specialist oversight essential

Coal tar (Goeckerman regimen: tar + UVB)

Traditional Use
Benefits for Psoriasis

Historical regimen effective in plaque psoriasis

Benefits for Phototherapy

Tar may enhance UV efficacy and reduce required doses

Odor/messiness; potential irritant; modern use limited to select centers

Medical Perspectives

Western Perspective

In western medicine, phototherapy is an evidence‑based, guideline‑endorsed option for moderate to severe plaque psoriasis, particularly when topical therapy is insufficient and before or alongside systemic agents. UV light directly modulates pathogenic skin inflammation and abnormal keratinocyte proliferation.

Key Insights

  • NB‑UVB is preferred first‑line phototherapy for plaque psoriasis due to efficacy and favorable safety.
  • PUVA is more potent for thick or refractory plaques but carries higher long‑term carcinogenic risk, especially at high cumulative doses.
  • Home NB‑UVB can achieve outcomes comparable to clinic‑based therapy in selected, well‑supervised patients, improving access.
  • Combination strategies (with topical steroids, vitamin D analogs, or acitretin) can increase response and reduce cumulative UV exposure.
  • Monitoring focuses on erythema/burn risk, eye/genital protection, cumulative dose tracking, and skin cancer surveillance for higher‑risk regimens (notably PUVA).

Treatments

  • Narrowband UVB (311–313 nm)
  • PUVA (oral or bath psoralen + UVA)
  • Targeted phototherapy (308‑nm excimer) for localized plaques
  • Adjunctive topicals (steroids, vitamin D analogs)
  • Systemic adjuncts (acitretin, select biologics)
Evidence: Strong Evidence

Sources

  • Elmets CA et al. Joint AAD–NPF guidelines of care for the management and treatment of psoriasis with phototherapy. J Am Acad Dermatol. 2019.
  • Cochrane Skin Group. Phototherapy for psoriasis: systematic reviews (2019–2020).
  • Koek MBG et al. Home vs outpatient UVB phototherapy for psoriasis: RCT. BMJ. 2009;338:b1542.
  • Stern RS. The risk of squamous cell carcinoma in PUVA‑treated patients. N Engl J Med. 1997.
  • Menter A et al. AAD psoriasis guidelines: systemic nonbiologics and phototherapy. J Am Acad Dermatol. 2020.

Eastern Perspective

Traditional systems have long recognized the therapeutic role of sunlight and heat for chronic skin conditions. While modern, device‑based phototherapy is a western clinical development, its principles resonate with older practices such as controlled sun exposure (heliotherapy), use of photosensitizing botanicals, and therapies aimed at clearing heat, reducing wind, and supporting detoxification and stress resilience.

Key Insights

  • Ayurveda and certain naturopathic traditions historically used graded sun exposure for skin disorders, with emollients and calming herbs to reduce irritation.
  • Psoralea corylifolia (bakuchi/babakuchi), rich in psoralens, has been used topically with sun exposure; modern medicine parallels this concept with PUVA, though safety and standardization differ.
  • TCM conceptualizes psoriasis with patterns of Blood Heat, Dampness, and Wind; treatments aim to cool heat and move blood, sometimes combined with external light or heat therapies.
  • Mind–body and stress‑reduction practices (yoga, meditation, acupuncture) are used to modulate flare triggers and itch perception, complementing light‑based care.
  • Integrative approaches often combine gentle emollients, anti‑inflammatory diets, and cautious natural photosensitizers with supervised sun exposure; evidence remains limited and variable.

Treatments

  • Graded sunlight (heliotherapy) timed to tolerance
  • Topical botanical emollients (e.g., coconut/sesame oil) to soothe plaques
  • Selective use of photosensitizing herbs (e.g., bakuchi) under expert supervision
  • Acupuncture and stress‑reduction practices to address triggers/itch
  • Naturopathic support for barrier function and inflammation
Evidence: Traditional Use

Sources

  • Sharma VK, Sahni K. Heliotherapy and natural psoralens in dermatology: historical perspective. Indian J Dermatol Venereol Leprol.
  • Zhang CS et al. Herbal medicine for psoriasis: systematic reviews suggest potential but heterogeneous evidence. J Altern Complement Med.
  • WHO. Traditional Medicine Strategy documents highlighting phototherapy analogs (heliotherapy).
  • Integrative dermatology texts discussing TCM/Ayurvedic frameworks for psoriasis.

Evidence Ratings

NB‑UVB 2–3 times weekly for 8–12 weeks leads to marked improvement or clearance in a majority of plaque psoriasis patients.

Elmets CA et al. AAD–NPF Phototherapy Guidelines. J Am Acad Dermatol. 2019.

Strong Evidence

PUVA achieves higher clearance rates and longer remissions than NB‑UVB in thick or extensive plaques but carries greater long‑term skin cancer risk.

Stern RS. Long‑term PUVA follow‑up on SCC/melanoma risk. N Engl J Med. 1997; JAMA Derm. 2012.

Strong Evidence

Home NB‑UVB, when prescribed and monitored, is non‑inferior to outpatient UVB in efficacy and safety for suitable patients.

Koek MBG et al. BMJ. 2009;338:b1542.

Moderate Evidence

Combining acitretin with UV therapy improves clearance and reduces cumulative UV exposure compared with UV alone.

Tanew A et al. Acitretin plus UVB/PUVA trials; AAD guidelines summary.

Moderate Evidence

Topical corticosteroids or vitamin D analogs used with UVB enhance response and may allow lower UV doses.

Cochrane reviews of topical plus phototherapy combinations; AAD guidelines.

Moderate Evidence

NB‑UVB has not shown a clear increase in melanoma or non‑melanoma skin cancer in most cohort studies, though long‑term risk cannot be excluded.

Observational phototherapy registries and guideline risk summaries (AAD/BAD).

Moderate Evidence

Western Medicine Perspective

Psoriasis arises from an interplay between genetic susceptibility and immune dysregulation that accelerates keratinocyte turnover and sustains cutaneous inflammation. Phototherapy leverages ultraviolet light to counter these processes where they occur: within the skin. Narrowband UVB (311–313 nm) is now the preferred first‑line light modality for plaque psoriasis. Delivered two to three times weekly with careful dose escalation, NB‑UVB induces apoptosis of epidermal T cells, suppresses pro‑inflammatory cytokine signaling (including the IL‑17/IL‑23 axis), and normalizes keratinocyte differentiation. Clinically, many patients show visible improvement within 3–6 weeks and achieve substantial clearance by 20–30 treatments. PUVA—psoralen plus UVA—penetrates deeper and can be more effective for thick or refractory plaques, often requiring fewer sessions and conferring longer remission; however, decades of follow‑up link high cumulative PUVA exposure with increased squamous cell carcinoma risk and, after extensive courses, melanoma risk, necessitating lifetime dose tracking and skin cancer surveillance. Evidence syntheses and guidelines position phototherapy between topical therapy and systemic/biologic agents. Compared with topical monotherapy, NB‑UVB offers broader and more reliable control for moderate disease; in some studies it performs comparably to conventional systemics for selected patients, with fewer systemic adverse effects. Combination strategies optimize outcomes: emollients improve light penetration and comfort; topical corticosteroids or vitamin D analogs enhance clearance; acitretin paired with UV reduces cumulative light exposure while increasing efficacy. Targeted phototherapy (308‑nm excimer laser) benefits localized plaques, while home NB‑UVB can match clinic results under specialist supervision, improving access. Safety management focuses on preventing acute phototoxic erythema, protecting eyes and genital skin, and recognizing contraindications such as photosensitivity disorders, prior melanoma, or inability to adhere to monitoring. For many, phototherapy delivers effective, organ‑sparing disease control with predictable timelines, though relapse months after cessation is common and may prompt maintenance or rotation to other modalities.

Eastern Medicine Perspective

Traditional healing systems have long viewed controlled exposure to natural elements—light and heat—as supportive for chronic skin ailments. In Ayurveda and naturopathic practice, graded heliotherapy is paired with emollients and calming botanicals to soften plaques and reduce irritation, aligning with the modern understanding that barrier support enhances light’s benefits. The historical use of psoralen‑containing plants such as Psoralea corylifolia (bakuchi) with sunlight foreshadows the pharmacologic principle behind PUVA, while underscoring the importance of expert supervision to balance potential benefits with risks of burns and photosensitivity. Traditional Chinese Medicine interprets psoriasis through patterns such as Blood Heat, Dampness, and Wind. Treatments aim to clear heat, cool blood, and move stasis, often using internal formulas and external applications to reduce redness, scaling, and itch. Although classical TCM did not employ device‑based UV therapy, the therapeutic intent—modulating inflammatory heat at the skin’s surface—parallels phototherapy’s clinical effect. Mind–body practices, acupuncture, and stress‑reduction are incorporated to address psychosocial triggers known to exacerbate flares. In an integrative framework, modern phototherapy can be combined with traditional supports: gentle oils to maintain the barrier, dietary measures to calm systemic inflammation, and practices that enhance adherence and resilience. While rigorous clinical trials for many traditional approaches remain limited, their emphasis on individualized care, gradual dosing (titrating sun exposure), and attention to whole‑person factors complements the structured, protocol‑driven nature of phototherapy. Together, they offer a patient‑centered path that respects both the precision of modern light devices and the wisdom of measured engagement with natural light.

Sources
  1. Elmets CA, Lim HW, Stoff B, et al. Joint AAD–NPF guidelines of care for the management and treatment of psoriasis with phototherapy. J Am Acad Dermatol. 2019.
  2. Menter A, Gelfand JM, Connor C, et al. AAD guidelines of care for the management of psoriasis with systemic nonbiologic therapies. J Am Acad Dermatol. 2020.
  3. Cochrane Skin Group. Interventions for chronic plaque psoriasis: phototherapy sections. 2019–2020.
  4. Koek MBG, Buskens E, van Weelden H, et al. Home vs outpatient UVB phototherapy for psoriasis: randomised controlled trial. BMJ. 2009;338:b1542.
  5. Stern RS. The risk of squamous cell carcinoma in patients treated with PUVA. N Engl J Med. 1997;336:1041–1045; long‑term updates in JAMA Dermatol.
  6. British Association of Dermatologists guidelines for phototherapy. 2017–2018 updates.
  7. Yones SS, Palmer RA, Garibaldinos TM, Hawk JLM. Randomized trial of NB‑UVB vs PUVA in chronic plaque psoriasis. J Am Acad Dermatol. 2006.

Related Topics

Health Disclaimer

This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any supplement or medication regimen.